Status:
WITHDRAWN
Use of Bevacizumab to Modulate the Outcomes of Trabeculectomy Surgery
Lead Sponsor:
Nova Scotia Health Authority
Conditions:
Glaucoma
Eligibility:
All Genders
30+ years
Phase:
PHASE4
Brief Summary
Vascular epithelial growth factor (VEGF) plays a critical role in vessel growth and wound healing. Bevacizumab, a non specific VEGF inhibitor, has been successfully used for the treatment of eye disea...
Eligibility Criteria
Inclusion
- any type of glaucoma, except neovascular or inflammatory
- patients requiring trabeculectomy or combined cataract surgery with trabeculectomy surgery
Exclusion
- younger than 30 years of age
- previous ocular surgeries excepting cataract surgeries
- patients who have had or present with intraocular inflammation
- neovascular glaucoma
- patients who are aphakic
- diabetic retinopathy
Key Trial Info
Start Date :
July 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2016
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01229202
Start Date
July 1 2008
End Date
January 1 2016
Last Update
August 21 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CDHA
Halifax, Nova Scotia, Canada, B3H 2Y9